{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"Research Square"}],"indexed":{"date-parts":[[2025,12,27]],"date-time":"2025-12-27T08:41:33Z","timestamp":1766824893385,"version":"3.48.0"},"posted":{"date-parts":[[2025,12,1]]},"group-title":"In Review","reference-count":28,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2025,11,21]]},"abstract":"<title>Abstract<\/title>\n                <p>\n                  <bold>Background and Objectives:<\/bold>\n                  We examined the relationships between cerebrospinal fluid (CSF) amyloid-\u03b2, tau, p-tau, and cognition in an Alzheimer\u2019s Disease Neuroimaging Initiative (ADNI) dataset. Studies have examined the longitudinal relationships between CSF biomarkers for Alzheimer\u2019s disease (AD) and cognition, but there is discordance in the strength of associations between CSF amyloid-\u03b2, t-tau, or p-tau with cognition at different disease stages.\n                  <bold>Methods:<\/bold>\n                  The study included 665 patients from the combined ADNI dataset: 128 cognitively normal (CN), 175 with mild cognitive impairment (MCI), and 362 with AD dementia. All patients were amyloid-\u03b2\u2013positive according to established CSF amyloid-\u03b2 cut-off values. Cognitive assessments, diagnoses, and specimen collection\/processing were conducted via published standardized protocols. We examined cross-sectional baseline data and performed correlational and regression analyses to evaluate the associations between CSF biomarkers and assessments of learning, memory, executive function, language, attention, visuospatial skills, and activities of daily living.\n                  <bold>Results:<\/bold>\n                  In the MCI cohort, significant negative correlations were observed between CSF amyloid-\u03b2 and ADAS-Cog11 (r=-0.164, p=0.02, ADAS-Cog13 (r=-0.181, p=0.01), Trails B (r=0.11, p=0.04), and FAQ (r=-0.131, p=0.01). There were positive correlations between amyloid-\u03b2 and MMSE (r=0.149, p=0.004) and amyloid-\u03b2 and WMS-delayed recall (r=0.116, p=0.03). Statistically significant correlations were observed between CSF t-tau and p-tau and CDRSB (t-tau: r=0.105, p=0.047), ADAS-Cog11 (t-tau: r=0.114, p=0.03; p-tau-181: r=0.114, p=0.03), ADAS-Cog13 (t-tau: r=0.165, p=0.002; p-tau-181: r=0.162, p=0.002), RAVLT-forgetting (t-tau:\nr=0.173, p=0.001; p-tau-181: r=0.167, p=0.001), and WMS-delayed recall (t-tau: r=-0.237, p&lt;0.001 and p-tau-181: r=-0.235, p&lt;0.001). In the AD cohort, no statistically significant relationships were observed between CSF amyloid-\u03b2\u2081\u208b\u2084\u2082, t-tau, p-tau-181, and any of the cognitive scores.\n                  <bold>Discussion:<\/bold>\n                  The findings suggest that the relationship between CSF biomarkers and cognitive performance is strongest in MCI. The lack of significant correlations in the AD cohort may indicate other pathophysiological changes dominating cognitive dysfunction at this disease stage. Both tau and amyloid showed similar utility in reflecting cognitive impairment, in contrast to some reports in the literature. Further research is warranted to explore biomarker longitudinal impacts and their predictive values across the spectrum of cognitive impairment.\n                <\/p>","DOI":"10.21203\/rs.3.rs-8168314\/v1","type":"posted-content","created":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T08:42:37Z","timestamp":1764578557000},"source":"Crossref","is-referenced-by-count":0,"title":["Correlations of CSF Biomarkers of Alzheimer\u2019s Disease with Cognitive Measures in MCI and AD Dementia: A Cross-Sectional Analysis"],"prefix":"10.21203","author":[{"given":"Gabriel","family":"Bitar","sequence":"first","affiliation":[{"name":"Creighton University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sierra","family":"Alban","sequence":"additional","affiliation":[{"name":"Creighton University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kassu","family":"Beyene","sequence":"additional","affiliation":[{"name":"Barrow Neurological Institute"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Boris","family":"Decourt","sequence":"additional","affiliation":[{"name":"Texas Tech University Health Sciences Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shervin","family":"Harirchian","sequence":"additional","affiliation":[{"name":"Creighton University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marwan N.","family":"Sabbagh","sequence":"additional","affiliation":[{"name":"Barrow Neurological Institute"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/s41514-024-00136-6","article-title":"Cost of care for Alzheimer's disease and related dementias in the United States: 2016 to 2060","volume":"10","author":"Nandi A","year":"2024","unstructured":"Nandi A, Counts N, Broker J, et al. Cost of care for Alzheimer's disease and related dementias in the United States: 2016 to 2060. NPJ Aging. 2024;10:13.","journal-title":"NPJ Aging"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.nic.2005.09.009","article-title":"Pathophysiology of Alzheimer's disease","volume":"15","author":"Imbimbo BP","year":"2005","unstructured":"Imbimbo BP, Lombard J, Pomara N. Pathophysiology of Alzheimer's disease. Neuroimaging Clin N Am. 2005;15:727\u201353. ix.","journal-title":"Neuroimaging Clin N Am"},{"key":"ref3","first-page":"189","article-title":"Mini-mental state. A practical method for grading the cognitive state of patients for the clinician","volume":"12","author":"Folstein MF","year":"1975","unstructured":"Folstein MF, Folstein SE, McHugh PR. Mini-mental state. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189\u201398.","journal-title":"J Psychiatr Res"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1111\/j.1532-5415.2005.53221.x","article-title":"The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment","volume":"53","author":"Nasreddine ZS","year":"2005","unstructured":"Nasreddine ZS, Phillips NA, Bedirian V, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005;53:695\u20139.","journal-title":"J Am Geriatr Soc"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S1474-4422(09)70299-6","article-title":"Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade","volume":"9","author":"Jack CR","year":"2010","unstructured":"Jack CR Jr., Knopman DS, Jagust WJ, et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol. 2010;9:119\u201328.","journal-title":"Lancet Neurol"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.jalz.2011.03.003","article-title":"Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease","volume":"7","author":"Sperling RA","year":"2011","unstructured":"Sperling RA, Aisen PS, Beckett LA, et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7:280\u201392.","journal-title":"Alzheimers Dement"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1016\/j.jalz.2018.01.010","article-title":"CSF biomarkers of Alzheimer's disease concord with amyloid-beta PET and predict clinical progression: A study of fully automated immunoassays in BioFINDER and ADNI cohorts","volume":"14","author":"Hansson O","year":"2018","unstructured":"Hansson O, Seibyl J, Stomrud E, et al. CSF biomarkers of Alzheimer's disease concord with amyloid-beta PET and predict clinical progression: A study of fully automated immunoassays in BioFINDER and ADNI cohorts. Alzheimers Dement. 2018;14:1470\u201381.","journal-title":"Alzheimers Dement"},{"year":"2010","author":"Anoop A","key":"ref8","unstructured":"Anoop A, Singh PK, Jacob RS, Maji SK. CSF Biomarkers for Alzheimer's Disease Diagnosis. Int J Alzheimers Dis. 2010;2010."},{"key":"ref9","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1196\/annals.1379.012","article-title":"Imaging and CSF studies in the preclinical diagnosis of Alzheimer's disease","volume":"1097","author":"Leon MJ","year":"2007","unstructured":"de Leon MJ, Mosconi L, Blennow K, et al. Imaging and CSF studies in the preclinical diagnosis of Alzheimer's disease. Ann N Y Acad Sci. 2007;1097:114\u201345.","journal-title":"Ann N Y Acad Sci"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"275","DOI":"10.3389\/fnins.2018.00275","article-title":"An Algorithm for Preclinical Diagnosis of Alzheimer's Disease","volume":"12","author":"Khan TK","year":"2018","unstructured":"Khan TK. An Algorithm for Preclinical Diagnosis of Alzheimer's Disease. Front Neurosci. 2018;12:275.","journal-title":"Front Neurosci"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1002\/ana.21610","article-title":"Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects","volume":"65","author":"Shaw LM","year":"2009","unstructured":"Shaw LM, Vanderstichele H, Knapik-Czajka M, et al. Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol. 2009;65:403\u201313.","journal-title":"Ann Neurol"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1002\/alz.12356","article-title":"Towards clinical application of tau PET tracers for diagnosing dementia due to Alzheimer's disease","volume":"17","author":"Ossenkoppele R","year":"2021","unstructured":"Ossenkoppele R, Hansson O. Towards clinical application of tau PET tracers for diagnosing dementia due to Alzheimer's disease. Alzheimers Dement. 2021;17:1998\u20132008.","journal-title":"Alzheimers Dement"},{"key":"ref13","unstructured":"U. S. Food and Drug Administration. FDA Approves First Drug to Image Tau Pathology in Patients Being Evaluated for Alzheimer\u2019s Disease [online]. Available."},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Leuzy, A., Mattsson-Carlgren, N., Palmqvist, S., Janelidze, S., Dage, J. L., & Hansson,O. (2022). Blood\u2010based biomarkers for Alzheimer\u2019s disease. EMBO Molecular Medicine, 14(1), e14408. https:\/\/doi.org\/https:\/\/doi.org\/10.15252\/emmm.202114408","DOI":"10.15252\/emmm.202114408"},{"issue":"7","key":"ref15","doi-asserted-by":"publisher","first-page":"e70535","DOI":"10.1002\/alz.70535","article-title":"Alzheimer\u2019s Association Clinical Practice Guideline on the use of blood-based biomarkers in the diagnostic workup of suspected Alzheimer\u2019s disease within specialized care settings","volume":"21","author":"Palmqvist S","year":"2025","unstructured":"Palmqvist S, Whitson HE, Allen LA, Suarez-Calvet M, Galasko D, Karikari TK, Okrahvi HR, Paczynski M, Schindler SE, Teunissen CE, Zetterberg H, Carrillo MC, Edelmayer RM, Mahinrad S, McAteer MB, Kahale LA, Pahlke S, Tampi MP. Alzheimer\u2019s Association Clinical Practice Guideline on the use of blood-based biomarkers in the diagnostic workup of suspected Alzheimer\u2019s disease within specialized care settings. Alzheimer\u2019s Dement. 2025;21(7):e70535. https:\/\/doi.org\/https:\/\/doi.org\/10.1002\/alz.70535.","journal-title":"Alzheimer\u2019s Dement"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"338ra366","DOI":"10.1126\/scitranslmed.aaf2362","article-title":"Tau and Abeta imaging, CSF measures, and cognition in Alzheimer's disease","volume":"8","author":"Brier MR","year":"2016","unstructured":"Brier MR, Gordon B, Friedrichsen K, et al. Tau and Abeta imaging, CSF measures, and cognition in Alzheimer's disease. Sci Transl Med. 2016;8:338ra366.","journal-title":"Sci Transl Med"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"2866","DOI":"10.1007\/s00259-020-04758-2","article-title":"Regional [(18)F]flortaucipir PET is more closely associated with disease severity than CSF p-tau in Alzheimer's disease","volume":"47","author":"Wolters EE","year":"2020","unstructured":"Wolters EE, Ossenkoppele R, Verfaillie SCJ, et al. Regional [(18)F]flortaucipir PET is more closely associated with disease severity than CSF p-tau in Alzheimer's disease. Eur J Nucl Med Mol Imaging. 2020;47:2866\u201378.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/s13195-020-00665-8","article-title":"Normalization of CSF pTau measurement by Abeta(40) improves its performance as a biomarker of Alzheimer's disease","volume":"12","author":"Guo T","year":"2020","unstructured":"Guo T, Korman D, La Joie R, et al. Normalization of CSF pTau measurement by Abeta(40) improves its performance as a biomarker of Alzheimer's disease. Alzheimers Res Ther. 2020;12:97.","journal-title":"Alzheimers Res Ther"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1212\/WNL.0b013e3181af79e5","article-title":"MRI and CSF biomarkers in normal, MCI, and AD subjects: diagnostic discrimination and cognitive correlations","volume":"73","author":"Vemuri P","year":"2009","unstructured":"Vemuri P, Wiste HJ, Weigand SD, et al. MRI and CSF biomarkers in normal, MCI, and AD subjects: diagnostic discrimination and cognitive correlations. Neurology. 2009;73:287\u201393.","journal-title":"Neurology"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1590\/1516-4446-2018-0296","article-title":"Correlation between CSF biomarkers of Alzheimer's disease and global cognition in a psychogeriatric clinic cohort","volume":"41","author":"Radanovic M","year":"2019","unstructured":"Radanovic M, Oshiro CA, Freitas TQ, Talib LL, Forlenza OV. Correlation between CSF biomarkers of Alzheimer's disease and global cognition in a psychogeriatric clinic cohort. Braz J Psychiatry. 2019;41:479\u201384.","journal-title":"Braz J Psychiatry"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.jalz.2011.03.008","article-title":"The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease","volume":"7","author":"Albert MS","year":"2011","unstructured":"Albert MS, DeKosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7:270\u20139.","journal-title":"Alzheimers Dement"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","article-title":"The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease","volume":"7","author":"McKhann GM","year":"2011","unstructured":"McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7:263\u20139.","journal-title":"Alzheimers Dement"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"19024","DOI":"10.1038\/s41598-019-54204-z","article-title":"Predicting clinical decline and conversion to Alzheimer's disease or dementia using novel Elecsys Abeta(1\u201342), pTau and tTau CSF immunoassays","volume":"9","author":"Blennow K","year":"2019","unstructured":"Blennow K, Shaw LM, Stomrud E, et al. Predicting clinical decline and conversion to Alzheimer's disease or dementia using novel Elecsys Abeta(1\u201342), pTau and tTau CSF immunoassays. Sci Rep. 2019;9:19024.","journal-title":"Sci Rep"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"Hanseeuw, B. J., Betensky, R. A., Jacobs, H. I. L., Schultz, A. P., Sepulcre, J.,Becker, J. A., Cosio, D. M. O., Farrell, M., Quiroz, Y. T., Mormino, E. C., Buckley,R. F., Papp, K. v, Amariglio, R. A., Dewachter, I., Ivanoiu, A., Huijbers, W., Hedden,T., Marshall, G. A., Chhatwal, J. P., \u2026 Johnson, K. (2019). Association of Amyloid and Tau With Cognition in Preclinical Alzheimer Disease: A Longitudinal Study. JAMA Neurology, 76(8), 915\u2013924. https:\/\/doi.org\/10.1001\/jamaneurol.2019.1424.","DOI":"10.1001\/jamaneurol.2019.1424"},{"issue":"16","key":"ref25","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1212\/WNL.0000000000002593","article-title":"Longitudinal relationships among biomarkers for Alzheimer disease in the Adult Children Study","volume":"86","author":"Xiong C","year":"2016","unstructured":"Xiong C, Jasielec MS, Weng H, Fagan AM, Benzinger TLS, Head D, Hassenstab J, Grant E, Sutphen CL, Buckles V, Moulder KL, Morris JC. Longitudinal relationships among biomarkers for Alzheimer disease in the Adult Children Study. Neurology. 2016;86(16):1499\u2013506. https:\/\/doi.org\/10.1212\/WNL.0000000000002593.","journal-title":"Neurology"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"965","DOI":"10.3233\/JAD-142643","article-title":"Alzheimer's Disease Neuroimaging I. Tau and Amyloid-beta Cerebrospinal Fluid Biomarkers have Differential Relationships with Cognition in Mild Cognitive Impairment","volume":"47","author":"Malpas CB","year":"2015","unstructured":"Malpas CB, Saling MM, Velakoulis D, Desmond P, O'Brien TJ. Alzheimer's Disease Neuroimaging I. Tau and Amyloid-beta Cerebrospinal Fluid Biomarkers have Differential Relationships with Cognition in Mild Cognitive Impairment. J Alzheimers Dis. 2015;47:965\u201375.","journal-title":"J Alzheimers Dis"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.neurobiolaging.2019.03.016","article-title":"Relevance of the interplay between amyloid and tau for cognitive impairment in early Alzheimer's disease","volume":"79","author":"Timmers M","year":"2019","unstructured":"Timmers M, Tesseur I, Bogert J, et al. Relevance of the interplay between amyloid and tau for cognitive impairment in early Alzheimer's disease. Neurobiol Aging. 2019;79:131\u201341.","journal-title":"Neurobiol Aging"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"5888","DOI":"10.1038\/s41380-021-01263-2","article-title":"Alzheimer's Disease Neuroimaging I. Alzheimer's disease profiled by fluid and imaging markers: tau PET best predicts cognitive decline","volume":"26","author":"Bucci M","year":"2021","unstructured":"Bucci M, Chiotis K, Nordberg A. Alzheimer's Disease Neuroimaging I. Alzheimer's disease profiled by fluid and imaging markers: tau PET best predicts cognitive decline. Mol Psychiatry. 2021;26:5888\u201398.","journal-title":"Mol Psychiatry"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/www.researchsquare.com\/article\/rs-8168314\/v1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.researchsquare.com\/article\/rs-8168314\/v1.html","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,27]],"date-time":"2025-12-27T08:39:25Z","timestamp":1766824765000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.researchsquare.com\/article\/rs-8168314\/v1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,1]]},"references-count":28,"URL":"https:\/\/doi.org\/10.21203\/rs.3.rs-8168314\/v1","relation":{},"subject":[],"published":{"date-parts":[[2025,12,1]]},"subtype":"preprint"}}